Salvage peptide receptor radionuclide therapy with [¹⁷⁷Lu-DOTA,Tyr³]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.

ABSTRACT:

Purpose

Therapy with [¹⁷⁷Lu-DOTA,Tyr³]octreotate is effective in patients with grade I/II metastasized and/or inoperable bronchial neuroendocrine tumour (NET) or gastroenteropancreatic NET (GEP-NET). In this study, we investigated the efficacy and safety of salvage treatment with [¹⁷⁷Lu-DOTA,Tyr³]octreotate.

Methods

Patients with progressive bronchial NET or GEP-NET were selected for re-(re)treatment if they had benefited from initial peptide receptor radionuclide therapy (I-PRRT) with a minimal progression-free survival (PFS) of 18 months. Patients received an additional cumulative dose of 14.8 GBq of [¹⁷⁷Lu-DOTA,Tyr³]octreotate over two cycles per retreatment with PRRT (R-PRRT) or re-retreatment with PRRT (R

SUBMITTER: van der Zwan WA 

PROVIDER: S-EPMC6351514 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature